Literature DB >> 16514281

Identification of novel Leishmania major antigens that elicit IgG2a response in resistant and susceptible mice.

Mohammad Reza Mohammadi1, Majid Zeinali, Sussan K Ardestani, Amina Kariminia.   

Abstract

Experimental murine models with high, intermediate and low levels of genetically based susceptibility to Leishmania major infection reproduce almost entire spectrum of clinical manifestations of the human disease. There are increasing non-comparative studies on immune responses against isolated antigens of L. major in different murine strains. The aim of the present study was to find out whether there is an antigen that can induce protective immune response in resistant and susceptible murine strains. To do that, crude antigenic extract of procyclic and metacyclic promastigotes of L. major was prepared and subjected to SDS-PAGE electrophoresis. Western-blotting was used to search for antigen(s) capable of raising high antibody level of IgG2a versus IgG1 in the sera of both infected resistant and susceptible strains. Two novel antigens from metacyclic promastigotes of L. major (140 and 152 kDa) were potentially able to induce specific dominant IgG2a responses in BALB/c and C57BL/6 mice. The 2 antigens also reacted with IgG antibody of cutaneous leishmaniasis patients. We confirm that 140 and 152 kDa proteins of L. major promastigotes are inducing IgG production in mice and humans.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16514281      PMCID: PMC2532650          DOI: 10.3347/kjp.2006.44.1.43

Source DB:  PubMed          Journal:  Korean J Parasitol        ISSN: 0023-4001            Impact factor:   1.341


  16 in total

1.  Dynamics of the antibody response in patients with therapeutic or spontaneous cure of American cutaneous leishmaniasis.

Authors:  M E Brito; M G Mendonça; Y M Gomes; M L Jardim; F G Abath
Journal:  Trans R Soc Trop Med Hyg       Date:  2001 Mar-Apr       Impact factor: 2.184

2.  The humoral immune response to the kinetoplastid membrane protein-11 in patients with American leishmaniasis and Chagas disease: prevalence of IgG subclasses and mapping of epitopes.

Authors:  C Trujillo; R Ramírez; I D Vélez; C Berberich
Journal:  Immunol Lett       Date:  1999-12-01       Impact factor: 3.685

3.  Protection against Leishmania major infection by oligomannose-coated liposomes.

Authors:  Yoshitaka Shimizu; Kazuo Yamakami; Takao Gomi; Munehiro Nakata; Hideki Asanuma; Takushi Tadakuma; Naoya Kojima
Journal:  Bioorg Med Chem       Date:  2003-04-03       Impact factor: 3.641

4.  Identification of Leishmania major cysteine proteinases as targets of the immune response in humans.

Authors:  S Rafati; A H Salmanian; K Hashemi; C Schaff; S Belli; N Fasel
Journal:  Mol Biochem Parasitol       Date:  2001-03       Impact factor: 1.759

5.  Intralesional isotype profiles in human localized cutaneous leishmaniasis lesions.

Authors:  R Aragort De Rossell; M Calcagno; O Rossell; Z Maizo De Segnini; A M Rodríguez
Journal:  Int J Exp Pathol       Date:  2001-04       Impact factor: 1.925

6.  The Leishmania major LACK antigen with an immunodominant epitope at amino acids 156 to 173 is not required for early Th2 development in BALB/c mice.

Authors:  Ben L Kelly; Richard M Locksley
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

7.  Evaluation of antigens from various Leishmania species in a Western blot for diagnosis of American tegumentary leishmaniasis.

Authors:  Cely Cristina Martins Gonçalves; Edna Maria Vissoci Reiche; Benício Alves De Abreu Filho; Thais Gomes Verzignassi Silveira; Tânia Cristina Felizardo; Karoline Rocha Maia; Rafael Costacurta; Evandro José Padovesi; Benedito Prado Dias Filho; Shiduca Itow Jankevicius; José Vitor Jankevicius
Journal:  Am J Trop Med Hyg       Date:  2002-01       Impact factor: 2.345

8.  Antigenicity of Leishmania braziliensis histone H1 during cutaneous leishmaniasis: localization of antigenic determinants.

Authors:  Emma Carmelo; Enrique Martínez; Ana Cristina González; José Enrique Piñero; Manuel E Patarroyo; Antonio Del Castillo; Basilio Valladares
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

Review 9.  The murine model of infection with Leishmania major and its importance for the deciphering of mechanisms underlying differences in Th cell differentiation in mice from different genetic backgrounds.

Authors:  Alain Gumy; Jacques A Louis; Pascal Launois
Journal:  Int J Parasitol       Date:  2004-03-29       Impact factor: 3.981

Review 10.  Leishmania model for microbial virulence: the relevance of parasite multiplication and pathoantigenicity.

Authors:  Kwang-Poo Chang; Steven G Reed; Bradford S McGwire; Lynn Soong
Journal:  Acta Trop       Date:  2003-03       Impact factor: 3.112

View more
  4 in total

1.  Ox40L-Ox40 pathway plays distinct roles in regulating Th2 responses but does not determine outcome of cutaneous leishmaniasis caused by Leishmania mexicana and Leishmania major.

Authors:  Rashmi Tuladhar; Steve Oghumu; Ran Dong; Allison Peterson; Arlene H Sharpe; Abhay R Satoskar
Journal:  Exp Parasitol       Date:  2014-11-11       Impact factor: 2.011

2.  Protective effect of lectin from Synadenium carinatum on Leishmania amazonensis infection in BALB/c mice.

Authors:  Sandra R Afonso-Cardoso; Flavio H Rodrigues; Marcio A B Gomes; Adriano G Silva; Ademir Rocha; Aparecida H B Guimaraes; Ignes Candeloro; Silvio Favoreto; Marcelo S Ferreira; Maria A de Souza
Journal:  Korean J Parasitol       Date:  2007-12       Impact factor: 1.341

3.  Purification and biochemical characterization of two novel antigens from Leishmania major promastigotes.

Authors:  Majid Zeinali; Sussan K Ardestani; Amina Kariminia
Journal:  Korean J Parasitol       Date:  2007-12       Impact factor: 1.341

4.  Th1 Platform Immune Responses Against Leishmania major Induced by Thiol-Specific Antioxidant-Based DNA Vaccines.

Authors:  Fatemeh Tabatabaie; Mehdi Mahdavi; Sobhan Faezi; Abdolhossein Dalimi; Zohreh Sharifi; Lame Akhlaghi; Fatemeh Ghaffarifar
Journal:  Jundishapur J Microbiol       Date:  2014-02-01       Impact factor: 0.747

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.